Explore the words cloud of the TCRabX project. It provides you a very rough idea of what is the project "TCRabX" about.
The following table provides information about the project.
Coordinator |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address contact info |
Coordinator Country | Germany [DE] |
Total cost | 264˙110 € |
EC max contribution | 264˙110 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2017 |
Funding Scheme | MSCA-IF-GF |
Starting year | 2019 |
Duration (year-month-day) | from 2019-08-01 to 2022-07-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | CHARITE - UNIVERSITAETSMEDIZIN BERLIN | DE (BERLIN) | coordinator | 264˙110.00 |
2 | MONASH UNIVERSITY | AU (VICTORIA) | partner | 0.00 |
Demographic change includes population ageing, and incidence rates begin to increase for many types of cancer in middle-aged and elderly people. Traditional cancer treatment includes surgery, chemotherapy, and radiation therapy, while tumour immunotherapy by T cell receptor (TCR) gene transfer represents an alternative form of treatment. The transfer of tumour-specific TCR genes into patient’s peripheral blood lymphocytes targets cancer specifically and effectively. But while patient-derived low-affinity TCRs do not show therapeutic activity, optimal-affinity TCRs, as isolated from newly-generated antigen-negative humanized mice with a diverse human TCR repertoire, can effectively delay tumour regression. X-ray crystallography is a powerful tool of structural biology, which helps researchers to identify the three-dimensional (3D) structures of biological macromolecules such as TCRs complexed to their cognate peptide-loaded major histocompatibility complex (pMHC) molecules. Recent research uncovered the docking topologies of naturally selected TCRs, but therapeutically efficient optimal-affinity TCRs recognizing tumour-associated self-antigens, have not been analysed to date. The exceptional specificity of TCRs is determined by three complementarity-determining regions (CDRs) of the TCR alpha- and beta-chains. Biomedical research on TCR gene therapy and design of future clinical trials will hugely benefit from the identification of CDR-mediated contact points made between therapeutic TCRs and the pMHC on their target cells. TCRabX is an interdisciplinary research project investigating the 3D structures of 13 TCRs complexed to MHC-I or MHC-II, respectively. It connects innovative clinical immunology research in Berlin/Germany and world-class structural biology research in Melbourne/Australia. The proposed research will enhance the health and well-being of citizens in Europe and worldwide by supporting the advancement of cancer immunotherapy approaches.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TCRABX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TCRABX" are provided by the European Opendata Portal: CORDIS opendata.
Unravelling maintenance mechanisms of immune tolerance after termination of venom immunotherapy by means of clonal mast cell diseases
Read MoreIncreases biomass production and soil organic carbon stocks with innovative cropping systems under climate change
Read More